logo-loader
viewXenetic Biosciences

Xenetic Biosciences to validate pre-clinical data in CAR-T tech with process development exercise

Xenetic Biosciences Inc (NASDAQ:XBIO) CEO Jeffrey Eisenberg sat down with Proactive at the 2019 BIO Investor Forum in San Francisco.

The Massachusettes-based biopharma company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.

Quick facts: Xenetic Biosciences

Price: 1.12 USD

NASDAQ:XBIO
Market: NASDAQ
Market Cap: $6.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Klondike Gold work along the Lonestar fault sees high grade...

Klondike Gold (CVE: KG) CEO Peter Tallman sat down with Steve Darling from Proactive Vancouver to discuss his company selling their BC assets to Ximen mining. Peter talked about why they did it and what they received in return.  Tallman also told Proactive about the results from their...

1 hour, 8 minutes ago

2 min read